INDEMNIFICATION AGREEMENTIndemnification Agreement • October 3rd, 2017 • OptiNose, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is made as of [ ], 2017 by and between OptiNose, Inc., a Delaware corporation (the “Corporation”), in its own name and on behalf of its direct and indirect subsidiaries, and [ ], an individual (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Corporation and Indemnitee covering the subject matter of this Agreement.
OPTINOSE, INC.Non-Qualified Stock Option Agreement • October 3rd, 2017 • OptiNose, Inc. • Pharmaceutical preparations
OptiNose, Inc., a Delaware corporation (the “Company”), hereby grants an option to purchase shares of its Common Stock, $0.001 par value (the “Stock”) to the optionee named below. The terms and conditions of the option are set forth in this cover sheet, in the attachment (together with the cover sheet, the “Agreement”) and in the Company’s 2010 Stock Incentive Plan (the “Plan”).
OPTINOSE, INC.Joinder Agreement • October 3rd, 2017 • OptiNose, Inc. • Pharmaceutical preparations
OptiNose, Inc., a Delaware corporation (the “Company”), hereby grants an option to purchase shares of its Common Stock, $0.001 par value (the “Stock”) to the optionee named below. The terms and conditions of the option are set forth in this cover sheet, in the attachment (together with the cover sheet, the “Agreement”) and in the Company’s 2010 Stock Incentive Plan (the “Plan”).
FIRST AMENDMENT TO THE SECOND AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT OF OPTINOSE, INC.Registration Rights Agreement • October 3rd, 2017 • OptiNose, Inc. • Pharmaceutical preparations
THIS FIRST AMENDMENT TO THE SECOND AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Amendment”), dated as of October 2, 2017, by and among OptiNose, Inc., a Delaware corporation (the “Company”), and the holders of Series D Shares, Series C-2 Shares, Series C-1 Shares, Series C Shares and Series B Shares of the Company identified on the signature pages thereto (collectively, the “Investors”).
STOCKHOLDERS’ AGREEMENTStockholders’ Agreement • October 3rd, 2017 • OptiNose, Inc. • Pharmaceutical preparations • New York
THIS STOCKHOLDERS’ AGREEMENT (the “Agreement”), dated as of October 2, 2017, by and among OptiNose, Inc., a Delaware corporation (the “Company”) and the Avista Investors (as defined below).
FIRST AMENDMENT TO THE SECOND AMENDED AND RESTATED SHAREHOLDERS AGREEMENT OF OPTINOSE, INC.Shareholders Agreement • October 3rd, 2017 • OptiNose, Inc. • Pharmaceutical preparations
THIS FIRST AMENDMENT TO THE SECOND AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT (this “Amendment”), dated as of October 2, 2017, by and among OptiNose, Inc., a Delaware corporation (the “Company”), the Investors, the Existing Shareholders and the Management Shareholders party thereto.
OPTINOSE, INC.Non-Qualified Stock Option Agreement • October 3rd, 2017 • OptiNose, Inc. • Pharmaceutical preparations
OptiNose, Inc., a Delaware corporation (the “Company”), hereby grants an option to purchase shares of its common stock, $0.001 par value per share (the “Stock”), to the optionee named below (the “Option”). The terms and conditions of the Option are set forth in this cover sheet, in the attachment (together with the cover sheet, the “Agreement”) and in the Company’s 2010 Stock Incentive Plan, as amended and restated as of September 19, 2017 (the “Plan”).
